연구성과로 돌아가기
2023 연구자 정보 (1052 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Lee, Jeeyun (Lee, J) |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea |
I-7171-2015 Lee, Jeeyun |
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer [JCR상위 28.4] Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response [JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer |
SCIE | 1.7 | ONCOLOGY |
hc111.kim@samsung.com;shty1@daum.net; hyosong77@yuhs.ac; |
||
|
Lian, Q. (Lian, Q) |
Genentech Inc, San Francisco, CA USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Lim, Ho Yeong (Lim, HY) |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea |
KBA-8868-2024 Lim, Ho Yeong |
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer [JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) |
SCIE | 1.7 | ONCOLOGY | hc111.kim@samsung.com;shty1@daum.net; | ||
|
Lim, Sung Hee (Lim, SH) |
제1저자 | Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea |
|
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer | SCIE | 68.8 | ONCOLOGY | hc111.kim@samsung.com;shty1@daum.net; | |
|
Nakamura, S. (Nakamura, S) |
Himeji Red Cross Hosp, Himeji, Hyogo, Japan |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Numata, K. (Numata, K) |
Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Park, Young Suk (Park, YS) |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul, South Korea Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, 81 Irwon Ro, Seoul, South Korea Seoul Natl Univ, Dept Surg, Bundang Hosp, Seongnam, South Korea Seoul Natl Univ, Bundang Hosp, Dept Surg, Seongnam, South Korea |
AAV-3491-2020 park, youngsuk |
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer [JCR상위 81.5] Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study [JCR상위 50.5] Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen [JCR상위 34.6] Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach [JCR상위 34.6] Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach (vol 23, pg 3, 2023) |
SCIE | 34.6 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY |
hc111.kim@samsung.com;shty1@daum.net; pys27hmo@skku.edu; jkk21c@knu.ac.kr; hyesukhan@chungbuk.ac.kr;nam20131114@gmail.com;seongho.kong@snu.ac.kr; |
||
|
Spahn, J. (Spahn, J) |
Genentech Inc, San Francisco, CA USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Tak, W-Y (Tak, WY) |
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Trojan, J. (Trojan, J) |
제1저자 | Univ Klinikum Frankfurt, Frankfurt, Germany |
C-1616-2009 Trojan, Jörg |
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | ||
|
Uguen, T. (Uguen, T) |
Hosp Pontchaillou, Rennes, France |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Wang, L. (Wang, L) |
Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China Chinese Acad Sci, Inst Elect Engn IEE, Beijing 100190, Peoples R China Chinese Acad Sci, IEE, Beijing 100190, Peoples R China |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation [JCR상위 6.7] Properties of Cosmic-Ray Sulfur and Determination of the Composition of Primary Cosmic-Ray Carbon, Neon, Magnesium, and Sulfur: Ten-Year Results from the Alpha Magnetic Spectrometer [JCR상위 6.7] Temporal Structures in Electron Spectra and Charge Sign Effects in Galactic Cosmic Rays |
SCIE | 6.7 |
ONCOLOGY PHYSICS, MULTIDISCIPLINARY |
|||
|
Wen, X. (Wen, X) |
1st Hosp Jilin Univ, Jilin, Jilin, Peoples R China |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Wu, C. (Wu, C) |
Roche Holding Ltd, Shanghai, Peoples R China |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Yopp, A. (Yopp, A) |
UT Southwestern Med Ctr, Dallas, TX USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY |
페이지 이동: